Point: Should radiotherapy after surgery for ductal carcinoma in situ be standard practice?

Current management of ductal carcinoma in situ (DCIS) is driven by multiple landmark trials showing that lumpectomy should be coupled with radiotherapy to reduce rates of local recurrence and later with anti-oestrogen therapy to maximise local control. However, the clinical and genomic landscape of DCIS is now better understood, and treatment can be risk stratified to limit not only the intensity and toxicities of treatment, but also its physical, emotional, and financial consequences.
Cancer Network